Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

61.84 -0.75 (-1.20%)
Streaming Delayed Price Updated: 10:35 AM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,339,034
Open 67.91
Bid (Size) 61.87 (2)
Ask (Size) 62.00 (2)
Prev. Close 62.59
Today's Range 61.31 - 68.26
52wk Range 38.94 - 86.95
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is CRISPR Therapeutics (CRSP) Stock Moving Today?
CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials. 
Via InvestorPlace
Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months
The agency said it will make an approval decision on Crispr's exa-cel in December. 
Via Investor's Business Daily

Performance

YTD
+50.83%
+50.83%
1 Month
-2.49%
-2.49%
3 Month
+35.05%
+35.05%
6 Month
+22.46%
+22.46%
1 Year
-16.24%
-16.24%

More News

Read More
Wall Street Loves These 3 Growth Stocks -- Should You?
Via The Motley Fool
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Can This Gene-Editing Stock Deliver 10X Returns?
Via The Motley Fool
CRISPR Therapeutics: A Galaxy's Worth of Deep Value
Via The Motley Fool
3 Disruptors I Love Right Now
Via The Motley Fool
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
Cathie Wood Is Buying the SEC Lawsuit Dip in Coinbase (COIN) Stock
Via InvestorPlace
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
Via InvestorPlace
CRISPR Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Expectations for CRISPR Therapeutics's Future
Via Benzinga
3 Top Healthcare Stocks to Buy for June
Via The Motley Fool
Prediction: These 2 Stocks Could Double In the Next Year
Via The Motley Fool
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
2 Supercharged Stocks to Buy With $100
Via The Motley Fool
2 Top Trends to Invest $5,000 in Right Now
Via The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health
Via The Motley Fool
A Good Week For The Market But A Pause In The Biotech Rally
Via Talk Markets
Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It
Via The Motley Fool
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
Via The Motley Fool
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
Via InvestorPlace
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Via MarketBeat
Exposures Product Safety
2 Stocks You'll Be Glad You Bought at These Prices
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.